US20160317467A1 - Method of treating or preventing infection - Google Patents
Method of treating or preventing infection Download PDFInfo
- Publication number
- US20160317467A1 US20160317467A1 US15/209,365 US201615209365A US2016317467A1 US 20160317467 A1 US20160317467 A1 US 20160317467A1 US 201615209365 A US201615209365 A US 201615209365A US 2016317467 A1 US2016317467 A1 US 2016317467A1
- Authority
- US
- United States
- Prior art keywords
- treat
- pharmaceutical composition
- prevent infection
- recited
- acceptable carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract 14
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 19
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 19
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 19
- 229960002675 xylitol Drugs 0.000 claims abstract description 19
- 235000010447 xylitol Nutrition 0.000 claims abstract description 19
- 239000000811 xylitol Substances 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 12
- 210000001072 colon Anatomy 0.000 claims description 8
- 244000052769 pathogen Species 0.000 claims description 7
- 230000000845 anti-microbial effect Effects 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 241000792859 Enema Species 0.000 claims description 4
- 239000007920 enema Substances 0.000 claims description 4
- 229940095399 enema Drugs 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 239000004599 antimicrobial Substances 0.000 claims 3
- 210000000981 epithelium Anatomy 0.000 claims 3
- 210000004400 mucous membrane Anatomy 0.000 claims 3
- 241000192125 Firmicutes Species 0.000 claims 2
- 150000003751 zinc Chemical class 0.000 claims 2
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 229940113601 irrigation solution Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 description 8
- 210000000436 anus Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 208000032376 Lung infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 244000000022 airborne pathogen Species 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- -1 pentose polyol Chemical class 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the field of the invention is anti-microbial therapy.
- One object of the invention is to develop a novel antimicrobial. Another object of the invention is to develop a preventative treatment for airborne pathogens to arrest epidemics. Yet another object of the invention is to develop a pathogen mitigating enema. Another object of the invention is to develop a pathogen mitigating solution to target bacteria in the ears, lungs, throat, colon, anus, and bladder. Another object of the invention is to develop delivery systems which would target specific, localized areas, such as an enema for the colon, peri-anal wipe for the anus, syringe for bladders, ear dropper for ears, inhaler or nebulizer for lungs, and spritz or pre-moistened towelette for cleaning surfaces.
- Another object is gargle for the throat, and a product combining zinc with xylitol, to minimize upper respiratory symptoms.
- the invention is the use of xylitol as a microbial infection inhibitor for non-sinus, non-oral, treatments.
- Xylitol is a pentose polyol which has ligand-molecule interactions with many binding site proteins and polysaccharides found in pathogen attachment mechanisms. A solution of xylitol will therefore form complexes with the binding sites and inhibit microbial attachment. Attachment is the first step in many human pathogen infections by microbes.
- a solution of 10% xylitol in water w/w is sprayed into the ambient air via a mister during an outbreak of airborne microbe borne infection epidemic.
- the solution ranging from 1%-95% xylitol in a carrier is injected into the lower colon via an enema to reduce colon mucus microbial attachment.
- the solution of xylitol is inhaled into the lungs via an atomizer to prevent or neutralize lung infections.
- a xylitol paste with 95% xylitol w/w and 5% w/w alcohol is applied via application tube to the anus.
- a 8% w/w xylitol in physiological buffered solution is introduced to the bladder via a catheter in a syringe to prevent bladder infection.
- a 1% to 95% solution of xylitol in a carrier is also contemplated.
- a solution of 10% w/w xylitol is blended with a variety of oils in an emulsion for use as a skin cream cosmetic with antimicrobial properties.
- 10% w xylitol is mixed with a ethanol-water solution for use as hand sanitizer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A method of treating and preventing infection using an effective concentration of xylitol in a pharmaceutical composition.
Description
- This Continuation application claims priority to and the benefit of U.S. patent application Ser. No. 14/287,165, filed May 26, 2014, the disclosures of which are incorporated herein in their entirety by reference.
- The field of the invention is anti-microbial therapy.
- In U.S. Pat. No. 8,680,263, Kozlowski, et al. describe the use of compounds including polysaccharaides to form conjugates which can be used for drug delivery and purification. This is based upon the fact that polar organic functional groups can form weak interactions with drug molecules, which often have polar sections as well.
- One object of the invention is to develop a novel antimicrobial. Another object of the invention is to develop a preventative treatment for airborne pathogens to arrest epidemics. Yet another object of the invention is to develop a pathogen mitigating enema. Another object of the invention is to develop a pathogen mitigating solution to target bacteria in the ears, lungs, throat, colon, anus, and bladder. Another object of the invention is to develop delivery systems which would target specific, localized areas, such as an enema for the colon, peri-anal wipe for the anus, syringe for bladders, ear dropper for ears, inhaler or nebulizer for lungs, and spritz or pre-moistened towelette for cleaning surfaces.
- Another object is gargle for the throat, and a product combining zinc with xylitol, to minimize upper respiratory symptoms.
- The invention is the use of xylitol as a microbial infection inhibitor for non-sinus, non-oral, treatments.
- Xylitol is a pentose polyol which has ligand-molecule interactions with many binding site proteins and polysaccharides found in pathogen attachment mechanisms. A solution of xylitol will therefore form complexes with the binding sites and inhibit microbial attachment. Attachment is the first step in many human pathogen infections by microbes.
- In one preferred embodiment of the invention, a solution of 10% xylitol in water w/w is sprayed into the ambient air via a mister during an outbreak of airborne microbe borne infection epidemic.
- In another preferred embodiment, the solution, ranging from 1%-95% xylitol in a carrier is injected into the lower colon via an enema to reduce colon mucus microbial attachment.
- In yet another preferred embodiment the solution of xylitol is inhaled into the lungs via an atomizer to prevent or neutralize lung infections.
- In yet another preferred embodiment, a xylitol paste with 95% xylitol w/w and 5% w/w alcohol is applied via application tube to the anus.
- In yet another preferred embodiment, a 8% w/w xylitol in physiological buffered solution is introduced to the bladder via a catheter in a syringe to prevent bladder infection. A 1% to 95% solution of xylitol in a carrier is also contemplated.
- In yet another preferred embodiment, a solution of 10% w/w xylitol is blended with a variety of oils in an emulsion for use as a skin cream cosmetic with antimicrobial properties.
- In yet another preferred embodiment, 10% w xylitol is mixed with a ethanol-water solution for use as hand sanitizer.
Claims (12)
1. A method to treat or prevent infection of the colon comprising: administering an anti-microbial adhesion inhibitor pharmaceutical composition for localized application via an enema solution to prevent and/or treat infections of the epithelial and mucosal tissues originating from pathogens from the list consisting of viruses, protozoans, gram negative and grain positive bacteria, and said composition comprising an active agent of xylitol present in a concentration of 1% to 95% by weight in a physiologically buffered acceptable carrier.
2. A method to treat or prevent infection of the colon as recited in claim 1 wherein said composition is used to treat pathogens from the list consisting of E. Coli, staphylococcus, streptococcus pneumonia, and Clostridium difficile in a pharmaceutical composition.
3. A method to treat or prevent infection of the colon as recited in claim 1 , wherein said acceptable carrier is water.
4. A method to treat or prevent infection of the colon as recited in claim 1 , wherein said acceptable carrier is a water and alcohol solution.
5. A method to treat or prevent infection using a pharmaceutical composition as recited in claim 1 wherein said xylitol is present in a concentration between 8% and 10% by weight in a pharmaceutical composition.
6. A method to treat or prevent infection as recited in claim 1 wherein said composition further comprises zinc salts.
7. A method to treat or prevent infection of the bladder comprising: administering an anti-microbial adhesion inhibitor pharmaceutical composition for localized application via a bladder irrigation solution to prevent and/or treat infections of the epithelial and mucosal tissues originating from pathogens from the list consisting of viruses, protozoans, gram negative and gram positive bacteria, and said composition comprising an active agent of xylitol present in a concentration of 1% to 95% by weight in a physiologically buffered acceptable carrier.
8. A method of treatment to treat or prevent infection using an antimicrobial adhesion inhibitor pharmaceutical composition for localized application in preventing and/or treating infections of the epithelial and mucosal tissues of a mammal's ear originating from pathogens from the list consisting of viruses, protozoans, gram negative and gram positive bacteria, and said composition consisting essentially of an active agent of xylitol present in a concentration of 1% to 95% by weight in an acceptable carrier in a pharmaceutical composition.
9. A method to treat or prevent infection of the bladder using a pharmaceutical composition as recited in claim 7 , wherein said acceptable carrier is water.
10. A method to treat or prevent infection of the bladder using a pharmaceutical composition as recited in claim 7 , wherein said acceptable carrier is a water and alcohol solution.
11. A method to treat or prevent infection using a pharmaceutical composition as recited in claim 7 wherein said xylitol is present in a concentration between 8% and 10% by weight in a pharmaceutical composition.
12. A method to treat or prevent infection as recited in claim 1 wherein said composition further comprises zinc salts.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/287,165 US20150011653A1 (en) | 2013-07-03 | 2014-05-26 | Novel Microbial Pathogen inhibitor |
| US201615209365P | 2016-07-13 | 2016-07-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/287,165 Continuation US20150011653A1 (en) | 2013-07-03 | 2014-05-26 | Novel Microbial Pathogen inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20160317467A1 true US20160317467A1 (en) | 2016-11-03 |
Family
ID=57226692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/209,365 Abandoned US20160317467A1 (en) | 2014-05-26 | 2016-07-13 | Method of treating or preventing infection |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US20160317467A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2022004843A1 (en) * | 2020-07-03 | 2022-01-06 |
-
2016
- 2016-07-13 US US15/209,365 patent/US20160317467A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2022004843A1 (en) * | 2020-07-03 | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6010224B2 (en) | Method of physical antimicrobial treatment | |
| CA3142109A1 (en) | Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract | |
| EP3650012A1 (en) | Solid composition comprising iodine agent and sodium chloride having improved water solubility, and antiviral and antimicrobial composition for eye, oral cavity, nasal cavity or inhalation containing aqueous solution thereof | |
| CN105979940A (en) | Materials and methods for controlling infections | |
| RU2010123052A (en) | AVENANTRAMID COMPOSITIONS | |
| CN101137357A (en) | Antimicrobial compositions containing esters of hydroxycarboxylic acids | |
| US20240016831A1 (en) | Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2 | |
| CA3142101A1 (en) | Methods and compositions for generating nitric oxide and uses thereof | |
| CN102448496A (en) | Pharmaceutical composition containing iodine and steroid and its use for treating rhinitis disease | |
| JP2015512386A5 (en) | ||
| CN102846655A (en) | Formulation and preparation method of antibacterial spray | |
| KR20070092095A (en) | Disinfection compositions and methods for their preparation and use | |
| RU2012149863A (en) | Polysaccharide of tamarind seed for use in the treatment of microbial infections | |
| CA3180336A1 (en) | Methods and compositions for treating and combatting tuberculosis | |
| JP5189291B2 (en) | Viricidal activity of cetylpyridinium chloride. | |
| SE1650162A1 (en) | Antimicrobial and cleansing composition comprising a polymeric biguanide, EDTA, and surfactants. | |
| US20210352905A1 (en) | Compositions and methods to disinfect, treat and prevent microbial infections | |
| US20160317467A1 (en) | Method of treating or preventing infection | |
| JP2020525526A (en) | Antiviral and antibacterial composition for eyes, oral cavity, nasal cavity or inhalation containing a solid composition containing an iodine agent and sodium chloride with improved water solubility and an aqueous solution thereof | |
| WO2014205159A1 (en) | Poloxamer based inhalation composition | |
| US20220054539A1 (en) | Disinfection and deodorizing of pap equipment using low concentration hypochlorous acid solutions | |
| WO2019215285A1 (en) | Substituted cyclodextrin-metal complexes and uses thereof | |
| US20150011653A1 (en) | Novel Microbial Pathogen inhibitor | |
| CN1812775B (en) | Use of pentane-1,5-diol in preparing medicine for inhibiting the growth of antibiotic-resistant of bacteria | |
| US20240066056A1 (en) | Formulations of a Prophylactic Nasal Spray and Methods of Use and Manufacture Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: DAA, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ARONOWITZ, ABBY, PH.D;REEL/FRAME:039155/0136 Effective date: 20150509 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |